

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT6465527

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
THERAVANCE RESPIRATORY COMPANY, LLC	12/10/2020
RECEIVING PARTY DATA	
Name:	THERAVANCE BIOPHARMA R&D IP, LLC
Street Address:	901 GATEWAY BLVD
City:	SOUTH SAN FRANCISCO
State/Country:	CALIFORNIA
Postal Code:	94080
PROPERTY NUMBERS Total: 14	
Property Type	Number
Application Number:	10854829
Application Number:	12069168
Application Number:	12756694
Application Number:	12984794
Application Number:	60473761
Application Number:	10813745
Application Number:	11983963
Application Number:	12891459
Application Number:	60459291
Application Number:	10992927
Application Number:	12001363
Application Number:	12001362
Application Number:	12903365
Application Number:	13550348
CORRESPONDENCE DATA	
Fax Number:	(650)808-6078
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	6508086000
Email:	patent@theravance.com

Correspondent Name:	THERAVANCE BIOPHARMA US, INC.
Address Line 1:	901 GATEWAY BLVD
Address Line 4:	SOUTH SAN FRANCISCO, CALIFORNIA 94080

ATTORNEY DOCKET NUMBER:	P-167
--------------------------------	-------

NAME OF SUBMITTER:	TIMOTHY R. WELCH
---------------------------	------------------

SIGNATURE:	/Timothy R. Welch/
-------------------	--------------------

DATE SIGNED:	12/22/2020
---------------------	------------

Total Attachments: 5

source=Second_TRC_Assignment-2020-12-10_Executed#page1.tif
source=Second_TRC_Assignment-2020-12-10_Executed#page2.tif
source=Second_TRC_Assignment-2020-12-10_Executed#page3.tif
source=Second_TRC_Assignment-2020-12-10_Executed#page4.tif
source=Second_TRC_Assignment-2020-12-10_Executed#page5.tif

Patent Assignment

WHEREAS, **Theravance Respiratory Company, LLC**, a limited liability company duly organized under and pursuant to the laws of Delaware and having its principal place of business at 1350 Old Bayshore Highway, Suite 400, Burlingame, CA 94010 U.S.A. (the "**Assignor**"), is the sole owner of the patents and patent applications listed in **EXHIBIT A** (such patents and patent applications and the inventions set forth therein are collectively the "**Assigned Patents**");

WHEREAS, **Theravance Biopharma R&D IP, LLC**, a limited liability company duly organized under and pursuant to the laws of Delaware and having its principal place of business at 901 Gateway Boulevard, South San Francisco, California 94080 U.S.A. (the "**Assignee**"), is desirous of acquiring Assignor's entire right, title and interest in and to the Assigned Patents, and in and to any subsequent patent applications and patents filed or granted thereon or therefrom, and Assignor is willing to assign its rights, title, and interest with respect thereto to the Assignee on the terms hereinafter set forth;

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Assignor does hereby sell, assign, transfer, set over and relinquishes exclusively unto the Assignee, its successors, legal representatives and assigns, Assignor's entire right, title and interest in and to: the Assigned Patents including, to the extent of Assignor's rights, the right to file patent applications on inventions set forth in the Assigned Patents; the right to claim priority to any of the Assigned Patents; the entire right, title and interest in and to any subsequent U.S. and foreign patent applications and patents claiming priority to any of the Assigned Patents, and in and to any U.S. and foreign patent applications and patents that claim priority to a patent application or patent arising from the Assigned Patents; any U.S. and foreign patents that may be granted on and from any of the Assigned Patents, any applications, divisionals, continuations, continuations-in-part, reexaminations, reissues, registrations, renewals, revalidations, substitutions, utility models, petty patents, extensions, and supplementary protection certificates that may be filed or granted on or for any of the Assigned Patents; all accrued causes of action for infringement of any of the foregoing; and all rights to and for the Assigned Patents under the Paris Convention for the Protection of Industrial Property; the same to be held and enjoyed by the Assignee, for its own use and behalf and for the use and behalf of its successors, legal representatives and assigns, to the full end of the term of the Assigned Patents and any such patents that may be granted thereon or therefrom as fully and entirely as if the same would have been held and enjoyed by the Assignor had this sale and assignment not been made.

AND for the same consideration, the Assignor hereby covenants and agrees to and with the Assignee, its successors, legal representatives and assigns, that the Assignor has not executed and will not execute any assignment, sale, agreement or encumbrance in conflict with this assignment.

AND for the same consideration, the Assignor hereby covenants and agrees to and with the Assignee, its successors, legal representatives and assigns that, at the Assignee's expense and reasonable request, the Assignor will take action and execute documents necessary to perfect the interest assigned herein.

AND for the same consideration, the Assignor hereby covenants and agrees to and with the Assignee, its successors, legal representatives and assigns that whenever counsel for the Assignee, or the counsel for its successors, legal representatives and assigns, shall advise that any proceeding, filing or other legal action in connection with the Assigned Patents or any patent applications and patents resulting therefrom is lawful and desirable, Assignor will, to the extent reasonable, sign all papers and documents, take all lawful oaths, and do all acts necessary or required to be done for the procurement, maintenance, enforcement and defense of the Assigned Patents and patent applications and patents resulting therefrom, without charge to the Assignor, its successors, legal representatives and assigns, but at the cost and expense of the Assignee, its successors, legal representatives and assigns.


AND the Assignor hereby requests the Director of the United States Patent and Trademark Office, and all foreign patent offices, to issue any and all patents resulting from the Assigned Patents or from any patent applications filed thereon or therefrom to the Assignee for the sole use and behalf of the Assignee, its successors, legal representatives and assigns.

[the remainder of this page intentionally left blank]

IN WITNESS WHEREOF, the parties hereby have executed this assignment on this 10th day of December 2020.

Theravance Respiratory Company, LLC


By: Innoviva, Inc. (its manager)

By: 

Name: Marianne Zhen

Title: Chief Accounting Officer

Theravance Biopharma R&D IP, LLC

By: 

Name: Jeffrey A. Hagenah

Title: Vice President, Legal & Chief Patent Counsel

EXHIBIT A

Title: Azabicycloalkane Compounds

Country	Status	Application Number	Application Date	Patent Number	Grant Date
Belgium - (BE)	Granted	04753585.1	05/27/2004	EP1626970	07/08/2009
France - (FR)	Granted	04753585.1	05/27/2004	EP1626970	07/08/2009
European Patent Convention - (EP)	Granted	04753585.1	05/27/2004	EP1626970	07/08/2009
Germany - (DE)	Granted	04753585.1	05/27/2004	EP1626970	07/08/2009
Italy - (IT)	Granted	04753585.1	05/27/2004	EP1626970	07/08/2009
Japan - (JP)	Granted	2006-533468	05/27/2004	4616264	10/29/2010
Patent Cooperation Treaty - (WO)	Inactive	PCT/US2004/016781	05/27/2004		
Spain - (ES)	Granted	04753585.1	05/27/2004	EP1626970	07/08/2009
United Kingdom - (GB)	Granted	04753585.1	05/27/2004	EP1626970	07/08/2009
United States - (US)	Granted	10/854829	05/27/2004	7358244	04/15/2008
United States - (US)	Granted	12/069168	02/07/2008	7732441	06/08/2010
United States - (US)	Granted	12/756694	04/08/2010	7893256	02/22/2011
United States - (US)	Inactive	12/984794	01/05/2011		
United States - (US)	Inactive	60/473761	05/28/2003		

Title: Diarylmethyl and Related Compounds

Country	Status	Application Number	Application Date	Patent Number	Grant Date
European Patent Convention - (EP)	Inactive	04758642.5	03/31/2004		
Japan - (JP)	Inactive	2006-509509	03/31/2004	4767842	06/24/2011
Japan - (JP)	Inactive	2010-233130	03/31/2004		
Patent Cooperation Treaty - (WO)	Inactive	PCT/US04/09825	03/31/2004		
United States - (US)	Inactive	10/813745	03/31/2004	7317102	01/08/2008
United States - (US)	Granted	11/983963	11/13/2007	7829728	11/09/2010
United States - (US)	Inactive	12/891459	09/27/2010	8008278	08/30/2011
United States - (US)	Inactive	60/459291	04/01/2003		

Title: Compounds Having β_2 Adrenergic Receptor Agonist and Muscarinic Receptor Antagonist Activity

Country	Status	Application Number	Application Date	Patent Number	Grant Date
Belgium - (BE)	Inactive	04811663.6	11/19/2004	EP1685118	07/08/2009
Canada - (CA)	Inactive	2543858	11/19/2004	2543858	04/15/2014
China P.R. - (CN)	Inactive	200480034201.8	11/19/2004	ZL200480034201.8	12/16/2009
European Patent Convention - (EP)	Inactive	04811663.6	11/19/2004	EP1685118	07/08/2009
France - (FR)	Inactive	04811663.6	11/19/2004	EP1685118	07/08/2009

Country	Status	Application Number	Application Date	Patent Number	Grant Date
Germany - (DE)	Inactive	04811663.6	11/19/2004	EP1685118	07/08/2009
Italy - (IT)	Inactive	04811663.6	11/19/2004	EP1685118	07/08/2009
Japan - (JP)	Inactive	2006-541552	11/19/2004	4851937	10/28/2011
Japan - (JP)	Inactive	2011-121065	11/19/2004		
Patent Cooperation Treaty - (WO)	Inactive	PCT/US2004/038975	11/19/2004		
Spain - (ES)	Inactive	04811663.6	11/19/2004	EP1685118	07/08/2009
United Kingdom - (GB)	Inactive	04811663.6	11/19/2004	EP1685118	07/08/2009
United States - (US)	Inactive	10/992927	11/19/2004	7345060	03/18/2008
United States - (US)	Granted	12/001363	12/11/2007	7838535	11/23/2010
United States - (US)	Granted	12/001362	12/11/2007	7842704	11/30/2010
United States - (US)	Inactive	12/903365	10/13/2010	8247564	08/21/2012
United States - (US)	Inactive	13/550348	07/16/2012		
United States - (US)	Inactive	60/524,34	11/21/2003		

[End of Exhibit A]